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Abstract: Since the approval of imatinib in 2001, kinase inhibitors have revolutionized
cancer therapies. Inside this family of phosphotransferases, casein kinase 2 (CK2) is of
great interest and numerous scaffolds have been investigated to design CK2 inhibitors.
Recently, functionalized indeno[1,2-b]indoles have been revealed to have high potency against
human cancer cell lines such as MCF-7 breast carcinoma and A-427 lung carcinoma.
4-Methoxy-5-isopropyl-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (THN7), identified as a
potent inhibitor of CK2 (IC50 = 71 nM), was selected for an encapsulation study in order to evaluate its
antiproliferative activity as THN7-loaded cyclodextrin nanoparticles. Four α-cyclodextrins (α-CDs)
were selected to encapsulate THN7 and all experiments indicated that the nanoencapsulation of this
CK2 inhibitor in α-CDs was successful. No additional surface-active agent was used during the
nanoformulation process. Nanoparticles formed between THN7 and α-C6H13 amphiphilic derivative
gave the best results in terms of encapsulation rate (% of associated drug = 35%), with a stability
constant (K11) of 298 mol·L−1 and a size of 132 nm. Hemolytic activity of the four α-CDs was
determined before the in cellulo evaluation and the α-C6H13 derivative gave the lowest value of
hemolytic potency (HC50 = 1.93 mol·L−1). Only the THN7-loaded cyclodextrin nanoparticles showing
less toxicity on human erythrocytes (α-C6H13, α-C8H17 and α-C4H9) were tested against A-427 cells.
All drug-loaded nanoparticles caused more cytotoxicity against A-427 cells than THN7 alone. Based
on these results, the use of amphiphilic CD nanoparticles could be considered as a drug delivery
system for indeno[1,2-b]indoles, allowing an optimized bioavailability and offering perspectives for
the in vivo development of CK2 inhibitors.
Keywords: indeno[1,2-b]indole; CK2 inhibitor; cyclodextrin; nanoparticles; in cellulo; human
erythrocytes; A427 cells
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1. Introduction
The protein kinase CK2 is an ubiquitous and pleiotropic serine/threonine kinase with hundreds
of endogenous substrates that are implicated in a wide variety of cellular functions (e.g., growth,
proliferation, differentiation, apoptosis) [1]. CK2 is generally described as a tetrameric structure
composed of two catalytic (α or α′) and two regulatory (β) subunits. CK2 is involved in several
pathological processes [2] and it is especially linked to cancer such as leukemia [3,4], glioblastoma [5],
and hepatocellular carcinoma [6].
Researchers are currently exploring a wide range of scaffolds to design small molecule inhibitors
of CK2 [7]. Among these inhibitors, indeno[1,2-b]indole derivatives have been identified as
ATP-competitive inhibitors of CK2 [8,9]. Structure-Activity Relationship (SAR) studies through the
systematic modification of the four rings A-D brought to light the main positions that identified
potent inhibitors of CK2. In fact, the introduction of an alkoxy group in position 4 (ring A) [10]
or an alkyl group in position 7 [11] was associated with the most favorable inhibitory effects on
CK2. The 4-methoxy-5-isopropyl-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (THN7, Figure 1)
was identified as a potent inhibitor of CK2 (IC50 = 71 nM, unpublished data) and then selected for
new encapsulation in a set of amphiphilic cyclodextrins (CDs). A “proof of concept” study was
previously carried out and validated the use of these macrocyclic oligosaccharides as nanocarriers [12].
The investigation of drug formulations remains a key point in the use of bioactive molecules, especially
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diverse  biological  parameters  (e.g.,  potency,  absorption, distribution, metabolism,  excretion,  and 
toxicity  (ADMET)  properties)  [13,14]. Moreover,  amphiphilic  cyclodextrin  derivatives  have  been 
developed  [15–17]  in  order  to  favor  the  interaction  of  CDs with  cell membranes,  to  form  self‐
assembled nanoparticles for drug encapsulation, enhancing interaction with hydrophobic drugs [18]. 
For  example,  amphiphilic  cyclodextrins  are useful  to  formulate  stable nanoparticles of  acyclovir, 
without the use of any surfactant [19]. 
Hydrocarbonated and fluorinated amphiphilic α‐ and β‐CDs derivatives were well studied by 
our group, and  it has been shown  that  these molecules could  form very stable nanoparticles  that 








to demonstrate  (i)  the  safety profile of  the  four  α‐cyclodextrins used as nanocarriers  and  (ii)  the 
improved in cellulo activity of CK2 inhibitor THN7. Red blood cells (RBCs) and A‐427 cell line were 
selected to achieve our goal. 
Figure 1. Structure of THN7 derivative.
Over the years, cyclodextrins became efficient vehicles to solubilize drugs and then to
optimize diverse biological parameters (e.g., potency, absorption, distribution, metabolism, excretion,
and toxicity (ADMET) properties) [13,14]. Moreover, amphiphilic cyclodextrin derivatives have been
developed [15–17] in order to favor the interaction of CDs with cell membranes, to form self-assembled
nanoparticles for drug encapsulation, enhancing interaction with hydrophobic drugs [18]. For example,
amphiphilic cyclodextrins are useful to formulate stable nanoparticles of acyclovir, without the use of
any surfactant [19].
Hydrocarbonated and fluorinated amphiphilic α- and β-CDs derivatives were well studied
by our group, and it has been shown that these molecules could form very stable nanoparticles
that could entrap hydrophilic and hydrophobic drugs [20–22]. As demonstrated previously for an
indeno[1,2-b]indole analog [12], nanoparticles made from these derivatives can not only encapsulate
this CK2 inhibitor, but they can also release it in a controlled manner. We also demonstrated that
nanoparticles made from α-CDs derivatives (Figure 2) are more resistant than those made from β-CDs
derivatives, even if the complexations are weaker.
In this study, we investigated a new formulation study in which compound THN7 (cLogP 3.326,
www.molinspiration.com/cgi-bin/properties, accession date: 16 September 2017) is directly loaded
into α-cyclodextrin nanoparticles. Our works were for the first time completed by cell-based assays to
demonstrate (i) the safety profile of the four α-cyclodextrins used as nanocarriers and (ii) the improved
in cellulo activity of CK2 inhibitor THN7. Red blood cells (RBCs) and A-427 cell line were selected to
achieve our goal.
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hydrocarbonated  chain,  the  affinity  also  increased  (298 mol∙L−1  and  417 mol∙L−1  for  α‐C6H13  and   
α‐C8H17,  respectively), with  the  higher  association  constant  being  observed with  the  fluorinated 
analog α‐C4F9 (828 mol∙L−1). We also noticed that these values are in the same range as those observed 
previously by our group for another CK2 inhibitor. The differences in the behavior were quite similar: 







the  end  of  the  process,  for  each  amphiphilic  α‐cyclodextrin  used,  a  20‐mL  stock  solution  of 
nanoparticles containing 600 μM THN7 was obtained and then stored before use. 
Figure 2. Fluorinated and hydrocarbonated amphiphilic α-cyclodextrins used in this study.
2. Results
2.1. Characterization of THN7:Amphiphilic Cyclodextrin Inclusion Complexes
Due to its very simple utilization, UV/Vis spectrosc py is the method f choice for studying the
complexation between amphi ilic α-cyclodextrin derivatives and UV-visible THN7 molecules in
ethanol. It has also been chosen for comparison with previously obtained co stants determined by the
same technique [12]. By using Job and Benesi-Hildebrand plots, stoichiometry and stability constants
(K11), respectively, can be easily and rapidly determined. All a phiphilic CD derivatives form 1:1
complexes with THN7 (maximum at 0.5 ratio) (Supplementary Information (SI) Figures S1–S4) and
Benesi-Hildebrand plots are linear (SI Figure S5). The results obtained from these pl ts are given in
Table 1.
Table 1. Stoichiometry and stability consta ts (K11) of c mplexes in ethanol.





The chain lengths and nature on the α-cyclodextrin derivatives seem to have an impact on the
association at the molecular scale. Indeed, the K11 values increased with the chain length and were
higher in the fluorinated derivative. For α-C4H9 the complexation was weak (57 mol·L−1), meaning
that at the molecular level, it had no affinity for THN7. Nevertheless, by increasing the length of
the hydrocarbonated chain, the affinity also increased (298 mol·L−1 and 417 ol·L 1 for α-C6H13
and α-C8H17, respectively), with the higher association constant being observed with the fluorinated
analog α-C4F9 (828 mol·L−1). We also noticed that these values are in the same range as those observed
previously by our group for another CK2 inhibitor. The differences in the behavior were quite similar:
a higher association constant was observed with the fluorinated derivative [12]. All these observations
also indicate that the THN7 molecule should be located between the hydrophobic chains rather than
in the cyclodextrin cavity, as the molecule is too bulky to fit into the cavity.
2.2. THN7 Loading of Nanoparticles Based on Amphiphilic α-Cyclodextrins
The loading of THN7 into α-CDs nanoparticles was achieved as previously
described [12,20]. Ethanol w s used a an organic solvent b cause it s been shown that,
among other solvents, for na oparticle formation, ethanol gave the smallest pa ticle size and better
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polydispersity [23]. At the end of the process, for each amphiphilic α-cyclodextrin used, a 20-mL stock
solution of nanoparticles containing 600 µM THN7 was obtained and then stored before use.
Dynamic Light Scattering was employed for measuring sizes of the nanoparticles
(SI Figures S6–S9) and the percentage of associated drug was determined after two days. The results
are given in Table 2.
As seen in Table 2, the mean particle sizes varies from 66 to 132 nm. Unlike our previous
observations of another CK2 inhibitor [12], for the same chain length, fluorinated nanoparticles are
bigger (104 vs. 82 nm for α-C4F9 and α-C4H9, respectively). This may be due to the THN7 molecule′s
better affinity for these fluorinated derivatives at the molecular scale, implying either more molecules
inside the particles, or THN7 coating on the surface. Nevertheless, all of the particle size distributions
are monodisperse, with a low polydispersity index (<0.2).
Table 2. Mean diameter (nm) and polydispersity index (PdI) of nanospheres based on different
amphiphilic α-cyclodextrins and % of associated THN7.
α-Cyclodextrin Nanosphere Size (nm) PdI Associated THN7 (%)
C4H9 82.2 ± 0.2 0.07 ± 0.01 24 ± 3
C6H13 131.9 ± 0.4 0.07 ± 0.03 35 ± 2
C8H17 65.8 ± 3.0 0.18± 0.02 14 ± 5
C4F9 104.3 ± 1.0 0.09 ± 0.02 19 ± 3
The loading capacities ranged from 14 to 35% (for α-C8H17 and α-C6H13, respectively). This is
relatively low compared to the previous ones observed with another indenoindole derivative [12].
Nevertheless, it is worth noting that these encapsulation rates are still in the same range as those
observed for other systems. No correlation between the loading capacities and the association constant
determined at the molecular level was observed.
2.3. Controlled Release Studies
The in vitro release experiments were performed in order to confirm what has previously been
observed in similar systems: the benefit of nanoparticle encapsulation. Figure 3 displays the release












Table  2. Mean  diameter  (nm)  and  polydispersity  index  (PdI)  of  nanospheres  based  on  different 
amphiphilic α‐cyclodextrins and % of associated THN7. 
α‐Cyclodextrin  Nanosphere Size (nm) PdI Associated THN7 (%) 
C4H9  82.2 ± 0.2  0.07 ± 0.01  24 ± 3 
C6H13  131.9 ± 0.4  0.07 ± 0.03  35 ± 2 
C8H17  65.8 ± 3.0  0.18± 0.02  14 ± 5 
C4F9  104.3 ± 1.0  0.09 ± 0.02  19 ± 3 
The  loading capacities ranged from 14 to 35% (for α‐C8H17 and α‐C6H13, respectively). This  is 
relatively low compared to the previous ones observed with another indenoindole derivative [12]. 
Nevertheless,  it  is worth noting  that  these encapsulation rates are still  in  the same range as those 



























Figure 3. Release profiles f THN7 from loaded na ospheres. The data are the average of
three experiments and the error bars indicate the three experiments.
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In all cases, a fast release of up to 30% THN7 was observed within the first 30 min, followed by a
much more controlled delivery of THN7, meaning that some of the THN7 molecules were probably
coated on the surface of the nanospheres as expected before, and the remainder was solubilized inside
the hydrophobic core of the nanoparticles. Complete drug release was reached in 1 to 5 h, the longer
release being observed for the fluorinated derivative nanoparticles. This confirms the observations
made by Krafft et al. [24] on the better resistance and low permeability of fluorinated colloidal systems.
2.4. Hemolytic Activity of α-CD Nanoparticles
C4F9 showed a relatively high hemolytic effect as its HC50 value was 3.04 ± 0.22 mmol·L−1
compared to the other derivatives. The ranking of the hemolytic effect in the case of other α-CD
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Figure  4.  Hemolytic  effect  of  different  α‐CD  nanoparticles  on  human  red  blood  cells  (RBCs). 
Hemolysis  was  expressed  as  the  percentage  of  the  untreated  control  in  the  function  of  α‐CD 
nanoparticle  concentration. The positive control was purified water and  the negative  control was 
phosphate‐buffered saline (PBS). Values presented are means ± SD. All data were obtained from three 





lung  cancer  cells A427 with THN7 alone and each  solution of THN7‐loaded nanoparticles.  In all 
experiments THN7 was used at a final concentration of 6 μM. A427 cells were selected as a model 
because they have been reported to overexpress CK2α, the target of kinase inhibitors from the class 
of  indeno[1,2‐b]indoles [25,26]. Moreover, other  indenoindoles known to be potent CK2  inhibitors 
were described to have a significant antiproliferative effect on human A427 cells [8]. Cell viability of 
A427 cells was determined using an MTT assay, and the results are depicted in Figure 5. 
Figure 4. Hemolytic effect of different α-CD nanoparticles on human red blood cells (RBCs). Hemolysis
was expressed as the percentage of the untreated control in the function of α-CD nanoparticle
concentration. The positive control was purified water and the negative control was phosphate-buffered
saline (PBS). Values presented are means ± SD. All data were obtained from three independent
replicates, and in the same experiment, two to four parallel concentrations were measured. HC50 values
were calculated as follows: C6H13 = 1.93 ± 0.11 mmol·L−1, C4H9 = 2.59 ± 0.8 mmol·L−1, C8H17 = 2.79
± 0.75 mmol·L−1 and C4F9 = 3.04 ± 0.22 mmol·L−1.
2.5. Improved Cytotoxic Activity of THN7-Loaded α-Cyclodextrin Nanoparticles on A-427 Lung Cancer Cells
To evaluate the cytotoxic effect of THN7-loaded α-cyclodextrin nanoparticles, we treated human
lung cancer cells A427 with THN7 alone and each solution of THN7-loaded nanoparticles. In all
experiments THN7 was used at a final concentration of 6 µM. A427 cells were selected as a model
because they have been reported to overexpress CK2α, the target of kinase inhibitors from the class of
indeno[1,2-b]indoles [25,26]. Moreover, other indenoindoles known to be potent CK2 inhibitors were
described to have a significant antiproliferative effect on human A427 cells [8]. Cell viability of A427
cells was determined using an MTT assay, and the results are depicted in Figure 5.
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Figure 5. Cytotoxic activity of THN7-loaded α-cyclodextrin nanoparticles on A-427 lung cancer cells.
C4: C4H9; C6: C6H13; C8: C8H17. (+) loaded cyclodextrins; (−) empty cyclodextrins. Viability of A427
cells were determined using an MTT assay. The viability of cells treated with 1% of the appropriate
solvent was set 100%. Staurosporine served as a control for the correctly performance of the MTT assay
using A427 cells. In all experiments THN7 was used at a final concentration of 6 µM.
The viability of A427 cells was decreased to 75% after treatment with 6 µM THN7 for 24 h.
This effect is enhanced by an additional 20% in the case where cells were treated with α-cyclodextrin
nanoparticles loaded with THN7. Empty nanoparticles had no effect on cell viability. An additional
increase after 48 h incubation with or without nanoparticles was not observed.
After treatment with staurosporine at a concentration of 20 µM, cell viability was reduced to
a residual 20%. This de onstrated that the MTT assay worked properly for the determination of
cell viability of A427 cells. The cytotoxic effect of staurosporine on different cancer cell lines is well
documented by many investigations [27,28].
3. Discussion
Amphiphilic α-cyclodextrin derivatives spontaneously formed nanoparticles in water and
efficiently enclosed CK2 inhibitors. Unloaded cyclodextrin nanoparticles had no cytotoxic effect
on A-427 lung cancer cells, while THN7-loaded α-cyclodextrin nanoparticles had a more pronounced
cytotoxic effect after 24 and 48 h of exposure compared to THN7 alone. This phenomenon can be
explained by several mechanisms. First of all, the solubilization of THN7 by amphiphilic cyclodextrins
plays an important role in the improvement of its efficacy. The interaction of THN7 with cyclodextrin
nanoparticles can prevent its aggregation in water, thus the CK2 inhibitor will penetrate freely through
the cell membrane. On the other hand, it has also recently been revealed that both cyclodextrins [29,30]
and poly-cationic amphiphilic cyclodextrin complexes [31] are able to enter the cells by endocytosis.
Cellular internalization of loaded nanoparticles is a key step for their action and can highly increase
the intracellular CK2 inhibitor concentration. To test and visualize the cellular internalization of
amphiphilic α-cyclodextrin nanoparticles, the labeling of cyclodextrins with fluorophore is needed.
Using fluorescent techniques, the interactions of nanoparticles with cells can be revealed. Our further
aim is to functionalize the amphiphilic cyclodextrins by fluorophores and targeting moieties such
as folates [32] or specific binding proteins. Targeting receptors or membrane proteins can improve
the internalization efficiency, while by the fluorophores the intracellular distribution and fate of
nanoparticles can be visualized and determined. A novel, multi-functional nanoscale drug delivery
system, based on the nanoparticle formation of functionalized amphiphilic α-cyclodextrins, is under
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construction and will be tested on cancer cell lines. With a suitable targeting moiety, the in vivo efficacy,
distribution, and toxicity of this carrier system can be characterized and used to improve the CK2
inhibitory effect on animal tumor models.
4. Materials and Methods
4.1. Materials
All chemicals and phosphate buffer solution were purchased from Acros Organics or Sigma
Aldrich and used without further purification. Other solvents were of chemical grade and were
used as received. 4-methoxy-5-isopropyl-5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (THN7) was
synthetized according to the same procedure described by References [10,33]. The α-cyclodextrins were
purchased from Roquette Frères (Lestrem, France) and their modification to amphiphilic CDs (Figure 2)
was conducted according to the syntheses described previously by our group [34]. The structures and
the purities of these amphiphilic derivatives were confirmed by spectral experiments according to
techniques such as 1H and 13C NMR at 300 and 125 MHz, respectively, and MALDI mass spectroscopy.
In order to simplify the name of each compound, shorter names have been assigned. For example,
α-C4F9 refers to hexakis[6-deoxy-6-(3-perfluorobutylpropanethio)-2,3-di-O-methyl]-α-cyclodextrin.
4.2. Cell Culture
The nanoparticles were tested on the human lung cancer cell line A427, which was obtained
from the German Collection of Microorganisms and Cell Culture (DSMZ, Braunschweig, Germany).
A427 cells were grown at 37 ◦C in a humidified atmosphere of 5% CO2 in RPMI-1640 medium
supplemented with 10% fetal calf serum (FCS).
4.3. Characterization of Inclusion Complexes Using the UV/Vis Spectroscopy
The continuous variation method was used to determine the stoichiometry of the fluorinated and
hydrocarbonated amphiphilic cyclodextrin:THN7 complexes. Two solutions of equal concentration
(4 × 10−4 M) of amphiphilic α-CDs and THN7 were prepared in ethanol. These solutions were
mixed in different portions without variation of the final volume, and stirred for seven days.
The absorbency (Aread) of each solution was measured at 460 nm. The absorbency change (∆A)
was then calculated (∆A = Aread-AT). The Job plots showed a maximum at a specific molar ratio
indicating the stoichiometry of the complexes (see supporting information). For the determination of
the equilibrium constant (K), the double-reciprocal (Benesi/Hildebrand) plot was used as previously
described [22].
4.4. Preparation of Nanoparticles
These results being the continuity of those published previously [20], we used the same highly
loaded method: the THN7 loaded nanoparticles based on amphiphilic α-cyclodextrin derivatives were
prepared by the nanoprecipitation technique, using 10 mL of a 4 × 10−4 M solution of preformed 1:1
THN7:CD complexes overloaded with an additional 20 mL of a 4 × 10−4 M THN7 solution in ethanol
phase. This ethanolic solution (30 mL) was poured dropwise into deionized water (2 × 30 mL) and
stirred at 400 rpm. Solvent and a part of water were evaporated under reduced pressure, and the
total volume was adjusted to 20 mL with deionized water. The final concentration of THN7 in each
nanoparticle stock solution was 600 µM. In addition, a DMSO stock solution of THN7 was prepared
(also with a concentration of 600 µM).
4.5. Particle Size Measurements
The mean particle size (diameter, nm) and the polydispersity index (PDI) of nanospheres
were measured by dynamic light scattering using a NanoZS instrument (Malvern Instruments,
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Malvern, UK) [22]. The measurements were carried out at 25 ◦C. Each value was the average of
three measurements.
4.6. Determination of the Encapsulation Efficiency
For measuring the loading efficiency [12], after the formation of nanoparticle suspensions,
unbound THN7 molecules in the nanoparticle dispersions were separated by centrifugation at
50,000 rpm for 1 h at +4 ◦C by an Optima™ MAX-E centrifuge (Beckman-Coulter), in order to
settle down the loaded nanoparticles. The supernatant was removed. The precipitate was then dried
overnight and the resulting powder containing the loaded nanoparticles was dissolved in ethanol
to obtain a clear solution, the absorbance of which was analyzed using a spectrophotometer at a
wavelength of 460 nm for the calculation of the encapsulated drug quantity. Experiments were
conducted in triplicate. Loading capacity was expressed in terms of associated drug percentage:
Associated drug % = [determined drug quantity (µmol)]/[initial drug quantity (µmol)] × 100.
4.7. In Vitro-Controlled Release Profile
The suspensions of nanoparticles charged in THN7 (1 mL) were introduced into a dialysis tube
(Sigma, Pur-A-Lyzer Mega 1000 Dialysis Kit, MWCO: 1 kDa). This tube was then placed in PBS (pH 7.4
with a volume of 10 mL), at room temperature, for a period of time. Aliquots of 1 mL of the buffered
solution were taken from the media at specific time intervals and replaced by fresh PBS. The proportion
of released and encapsulated THN7 molecules were measured by UV spectrometry at 460 nm [12].
Experiments were conducted three times.
4.8. Hemolysis Test
A hemolysis test was performed on fresh human blood, collected from healthy donors [35].
Erythrocytes were separated from citrated blood by centrifugation at 2500× g for 10 min, washed
three times with PBS, and resuspended in the same solution. Aliquots of the cell suspension with
the respective RBC number of 5 × 107 were added to the PBS solution (pH 7.2) containing increasing
concentrations of the samples investigated in the study. After mixing them gently, each solution
was incubated at 37 ◦C for 10 min and then centrifuged at 5000× g. Finally, the absorbance of
the hemoglobin released into the supernatant was measured at 540 nm with a FLUOstar OPTIMA
Microplate Reader. The percentage of hemolysis was expressed as the ratio of hemoglobin in the
supernatant of the sample solutions related to the hemoglobin concentration after the complete
hemolysis of erythrocytes in water. The dose-response curve was determined, and the concentration
inducing hemolysis in 50% of the erythrocyte population (HC50) was subsequently calculated [36].
4.9. Cell Viability Assay
For the determination of cell viability of A427 cells, an MTT assay was performed. A427 cells
were seeded at a density of 104 cells per well into 96-well plates in 100 µL of growth medium.
After 24 h, the medium was replaced by fresh medium containing either a working solution containing
THN7 alone (1 µL of THN7 stock solution added to 99 µL medium) or a working solution of
THN7-loaded nanoparticles (1 µL of stock solution of THN7-loaded nanoparticles added to 99 µL
medium). Then, in each well the final concentration of THN7 (alone or in nanoparticle solution) was
6 µM. Blank experiments were also conducted with empty cyclodextrins. Medium containing 1% of
the solvent served as a control. The concentration of staurosporin used in the experiment was 0.5 µM.
After 24 h and 48 h, respectively, 10 µL of the MTT solution (5 mg/mL in PBS) were added to each well
and the plate was incubated for 2 h at 37 ◦C. The MTT assay is based on the ability of the mitochondrial
succinate-tetrazolium reductase system to convert 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) to the purple-colored formazan. The produced formazan was dissolved by the addition
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of 100 µL of the MTT stop solution (0.04 M HCl in isopropanol) and the plates were incubated for one
additional hour at 37 ◦C before recording the absorbance at 570 nm.
5. Conclusions
The development of advanced drug delivery systems dedicated to kinase inhibitors is important to
investigate for enhancing the uptake of anticancer drugs into tumors. In the present study, four α-CDs
were used to encapsulate an indenoindole-type CK2 inhibitor, THN7. All experiments indicated that
the nanoencapsulation of THN7 in α-CDs was successful. In parallel, after testing the hemolytic
activity of the four selected α-CDs, only three THN7-loaded cyclodextrin nanoparticles (α-C6H13,
α-C8H17, and α-C4H9) were tested against A-427 cells. It is important to note that all THN7-loaded
nanoparticles were more cytotoxic against A-427 cells than THN7 alone.
Further studies should be investigated to optimize the drug-loading capacity of our amphiphilic
α-cyclodextrin-based nanoparticles. In the present study, we only obtained an encapsulation rate
of 35% with the α-C6H13 amphiphilic derivative. The structural modulation of both amphiphilic
α-cyclodextrins and indeno[1,2-b]indoles could be rapidly achieved, giving new insight into
amphiphilic α-cyclodextrin derivatives for targeted drug delivery to tumors. As suggested in the
perspectives, we will examine how amphiphilic α-cyclodextrins could assist the bioactive molecule
(in this case, a CK2 inhibitor) to enhance in cellulo activity against cancer cells (e.g., A-427, MCF-7).
This is a crucial point to study before undertaking an in vivo development project.
Supplementary Materials: The following are available online at www.mdpi.com/1424-8247/11/1/10/s1. Figure
S1: Job plot for the complexation of THN7 with α-C4H9 amphiphilic derivative, Figure S2: Job plot for the
complexation of THN7 with α-C6H13 amphiphilic derivative, Figure S3: Job plot for the complexation of
THN7 with α-C8H17 amphiphilic derivative, Figure S4: Job plot for the complexation of THN7 with α-C4F9
amphiphilic derivative, Figure S5: Benesi-Hildebrand plot for amphiphilic α-cyclodextrins. THN7 at constant
concentration in the presence of increasing concentrations of amphiphilic α-CD derivatives at 256 nm, Figure
S6: Dynamic light scattering experiments spectra and mean diameter of THN7-loaded C4H9 amphiphilic CDs,
Figure S7: Dynamic light scattering experiments spectra and mean diameter of THN7-loaded C6H13 amphiphilic
CDs, Figure S8: Dynamic light scattering experiments spectra and mean diameter of THN7-loaded C8H17
amphiphilic CDs, Figure S9: Dynamic light scattering experiments spectra and mean diameter of THN7-loaded
C4F9 amphiphilic CDs.
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